NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biocartis today announced that it has licensed from Hospital del Mar in Spain the rights to an EGFR biomarker for colon cancer.

The Lausanne, Switzerland-based firm plans to develop an EGFR mutation test that can help doctors further refine the best responder population among colon cancer patients receiving EGFR inhibitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.